Interní Med. 2007; 9(6): 280-282

Is the patient in danger of recurrence of thromboembolic disease?

MUDr. Dalibor Musil Ph.D
Cévní ambulance a Ústav patologické fyziologie LF UP a FN Olomouc

The article discusses the optimal length of secondary thromboprophylaxis after thromboembolic disease (TEN) and the probability of TEN recurrence. An individual approach to patients after a TEN is underlined. It attempts to give physicians a guideline how to estimate in an individual patient a risk of recurrence of the disease. It shows that the answer to the question what is the optimal length of anticoagulation treatment lies in stratification to low and high risk patients according risk of TEN recurrence. The following parameters are currently used for this stratification-sex, D-dimer level during and after the anticoagulation treatment, presence of absence of active malignancy and thrombophilic state with high risk of recurrence, evidence of old postthrombotic changes on duplex ultrasound examination, TEN in past medical history.

Keywords: thromboembolic disease, phlebothrombosis, pulmonary embolism, secondary thromboprohylaxis, recurrence, thrombophilic state, vitamin K antagonists, anticoagulation therapy

Published: November 9, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Musil D. Is the patient in danger of recurrence of thromboembolic disease? Interní Med. 2007;9(6):280-282.
Download citation

References

  1. Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. N Engl J Med, 2004; 351: 268-277. Go to original source... Go to PubMed...
  2. Buliková A. Antifosfolipidový syndrom. Int Med pro Praxi, 2006; 8 (5), 240-243.
  3. Buller HR. Agnelli G. Hull RD. Hyers TM. Prins MH. Raskob GE.: Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004; 126 (3 Suppl): 401S-428S. Go to original source... Go to PubMed...
  4. Cosmi B. Palareti G. D-dimer, oral anticoagulation, and venous thromboembolism recurrence. Seminars in Vascular Medicin, 2005; 5: 365-370. Go to original source... Go to PubMed...
  5. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patiens with the antiphospholipid antibody syndrome. NEJM, 2003; 349: 1133-1138. Go to original source... Go to PubMed...
  6. Eichenger S, et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med, 2002; 162: 2357-2362. Go to original source... Go to PubMed...
  7. Hyers TH. Duration of anticoagulation in venous thromboembolis. Arch Int Med, 2003; 163: 1265-1266. Go to original source... Go to PubMed...
  8. Kahn SR, et al. Relationship between deep venous thrombosis and posttrombotic syndrome. Arch Int Med, 2004; 164: 17-26. Go to original source... Go to PubMed...
  9. Kakkos SK, Daskalopoulou SS, Daskalopoulos ME, Nicolaides AN, Geroulakos G. Review on the value of graduated elastic compression stockings after deep vein thrombosis. Thrombosis & Haemostasis, 2006; 96: 441-445. Go to original source... Go to PubMed...
  10. Kessler P. Antikoagulační léčba warfarinem. Int med pro Praxi, 2005; 7 (4): 182-185.
  11. Malý J, Widimský J. Otazníky kolem prevence a léčby tromboembolické nemoci v roce 2006. Int Med pro Praxi, 2006; 8 (4): 172-178.
  12. McRae S. Tran H. Schulman S. Ginsberg J. Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet, 2006; 368: 371-378. Go to original source... Go to PubMed...
  13. Murín J. Liečba hlbokej venóznej trombózy. Int Med pro Praxi, 2005; 7 (5): 265-266.
  14. Prandoni P. Risk factors of recurrent venous thromboembolism: the role of residual vein thrombosis. Pathophysiology of Haemostasis & Thrombosis. 2003 Sep - 2004 Dec. 33 (5-6): 351-353. Go to original source... Go to PubMed...
  15. Van den Belt AG, et al. Recurrence of venous thromboembolism in patiens with familial thrombophilia. Arch Int Med, 1997; 157: 2227-2232. Go to original source... Go to PubMed...
  16. Van Dongen CJJ, et al. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event (meta-analysis). Arch Int Med, 2003; 163: 1285-1289. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.